Inclusion Criteria:  Male or female patients aged ≥18 years; Patients enrolled on the same day as the first prescription with BDP/FF NEXThaler® 100/6 micrograms, or having ongoing treatment with BDP/FF NEXThaler® 100/6 micrograms started within the previous 14 days (maximum), as per local standard clinical practice. Not adequately controlled asthmatic patients (according to clinician's judgement) when BDP/FF NEXThaler® 100/6 micrograms was prescribed; Patients not treated with extrafine formulations during the 6 months before starting the treatment with BDP/FF NEXThaler®; Written informed consent to participate in the study and for the processing of personal data.  Exclusion Criteria:  Recent (i.e. within the last 6 months) history of life-threatening asthma exacerbations; Diagnosis of chronic obstructive pulmonary disease (COPD); Asthmatic patients on treatment with biologic agents (e.g. monoclonal antibodies) and/or extemporary or fixed triple combinations (e.g. long-acting β2 agonist (LABA)/long-acting muscarinic antagonist (LAMA)/inhaled corticosteroid (ICS) at any dose regimen; Patients with uncontrolled/clinically significant diseases (according to clinician's judgement) or inability to understand and fill in study questionnaires; Concomitant participation in experimental clinical studies/investigations or participation in experimental clinical studies/investigations within 3 months prior to enrolment into the present study.